Howe & Rusling’s Acorda Therapeutics ACOR Stock Holding History

Howe & Rusling’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1	Closed	-$2K	–	1091
2016 Q3	$2K	Buy	+1	New	+$2.98K	﹤0.01%	900

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Howe & Rusling's ACOR Position: Q4 2016 in Review

Howe & Rusling sold out of Acorda Therapeutics (ACOR) in Q4 2016, closing a stake of 1 share — an estimated $2K sold.

Howe & Rusling first reported a position in ACOR in Q3 2016 and held it in 1 quarter. The position peaked at $2K in Q3 2016. 175 funds tracked by Wall St. Rank hold ACOR as of Q4 2016.

Howe & Rusling reported no remaining Acorda Therapeutics position as of Q4 2016 after selling out during the quarter.
Howe & Rusling sold 1 Acorda Therapeutics share in Q4 2016, an estimated $2K.
Howe & Rusling first reported a position in Acorda Therapeutics in Q3 2016 and held it in 1 quarter.
Howe & Rusling's Acorda Therapeutics position peaked at $2K in Q3 2016.
175 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2016.

Based on Howe & Rusling's 13F filing for Q4 2016, filed 20 Jan 2017.